1. Coleman CN. Hypoxia in tumors: A paradigm for the approach to biochemical and physiological heterogeneity.J Natl Cancer Inst 80: 310–317, 1998.
2. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells.Cancer Res 41(1): 73–81, 1981.
3. Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells.Cancer Res 43: 1523–1528, 1983.
4. Jerabek PA, Patrick TB, Kilbourn MR, Dischino DD, Welch MJ. Synthesis and biodistribution of18F-labeled fluoromisonidazoles: potentialin vivo markers of hypoxic tissue.Int J Radiate App Instrum [A] 37: 599–605, 1986.
5. Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD, Wiebe LI. Radiolabeled 1-(5-iodo-5-deoxy-β-d-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia.J Nucl Med 32: 1764–1770, 1991.